Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Smith & Nephew Snats ADR (SNN)

Smith & Nephew Snats ADR (SNN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 14,207,371
  • Shares Outstanding, K 424,354
  • Annual Sales, $ 5,810 M
  • Annual Income, $ 412,000 K
  • EBIT $ 0 M
  • EBITDA $ 1,302 M
  • 60-Month Beta 0.63
  • Price/Sales 2.39
  • Price/Cash Flow 10.37
  • Price/Book 2.59

Options Overview Details

View History
  • Implied Volatility 70.35% (-4.05%)
  • Historical Volatility 41.47%
  • IV Percentile 84%
  • IV Rank 65.59%
  • IV High 92.17% on 04/17/25
  • IV Low 28.74% on 08/18/25
  • Expected Move (DTE 11) 4.38 (13.07%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 73
  • Volume Avg (30-Day) 9
  • Put/Call OI Ratio 0.19
  • Today's Open Interest 396
  • Open Int (30-Day) 374
  • Expected Range 29.10 to 37.86

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
31.95 +6.38%
on 11/20/25
33.99 unch
on 12/08/25
+0.76 (+2.29%)
since 11/07/25
3-Month
31.83 +6.79%
on 11/06/25
38.79 -12.37%
on 09/09/25
-4.41 (-11.48%)
since 09/08/25
52-Week
23.69 +43.48%
on 01/14/25
38.79 -12.37%
on 09/09/25
+8.63 (+34.03%)
since 12/06/24

Most Recent Stories

More News
Smith & Nephew Releases Six-Monthly Block Listing Return

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An update...

SNN : 33.99 (+1.52%)
BlackRock Adjusts Voting Rights in Smith & Nephew

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Smith & Nephew...

SNN : 33.99 (+1.52%)
Smith & Nephew (SN) was downgraded to a Hold Rating at Bernstein

Bernstein analyst Lisa Bedell Clive downgraded Smith & Nephew to a Hold today and set a price target of £14.00. The company’s shares opened today at p1,305.00.Elevate Your Investing Strategy: Take advantage...

SNN : 33.99 (+1.52%)
Smith+Nephew to Host Capital Markets Days in December 2025

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An announcement...

SNN : 33.99 (+1.52%)
Barclays Keeps Their Hold Rating on Smith & Nephew (SN)

Barclays analyst Hassan Al-Wakeel maintained a Hold rating on Smith & Nephew today and set a price target of £13.00. The company’s shares closed yesterday at p1,341.00.Elevate Your Investing Strategy:...

SNN : 33.99 (+1.52%)
Is Zimmer Biomet Stock Underperforming the Nasdaq?

Zimmer Biomet has underperformed the Nasdaq over the past year, but analysts are cautiously optimistic about the stock’s prospects.

ZBH : 94.71 (+0.46%)
SNN : 33.99 (+1.52%)
$NASX : 23,578.13 (+0.31%)
Zimmer Biomet Focuses on Innovation Amid Growing Competition

Zimmer Biomet Holdings, Inc. ZBH is participating in the ongoing American Academy of Orthopaedic Surgeons (AAOS) 2025 Annual Meeting in San Diego, from March 10-14. Here, the company is highlighting advancements...

ZBH : 94.71 (+0.46%)
SNN : 33.99 (+1.52%)
SYK : 362.03 (-0.55%)
JNJ : 201.86 (-0.03%)
SNN Stock May Gain Following the Co-Marketing Deal With JointVue

Smith & Nephew SNATS SNN recently announced the signing of a co-marketing agreement with JointVue for its patented OrthoSonic 3D Surgery Planning Technology, which is the only ultrasound device currently...

SNN : 33.99 (+1.52%)
BSX : 97.36 (-0.16%)
BAX : 18.69 (+0.81%)
DVA : 117.39 (+0.09%)
SNN Boosts Knee Revision Surgery With Its LEGION Hinged Knee System

Smith & Nephew SNATS SNN recently launched its LEGION Hinged Knee System, which incorporates its proprietary OXINIUM Technology. The launch marks a significant advancement in the field of knee revisions,...

ZBH : 94.71 (+0.46%)
SNN : 33.99 (+1.52%)
SYK : 362.03 (-0.55%)
MDT : 101.40 (+0.04%)
Smith+Nephew opens new state-of-the-art surgical innovation and training centre in the heart of Munich

/PRNewswire/ -- Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company specialising in orthopaedics, advanced wound management and sports...

SNN : 33.99 (+1.52%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

Smith & Nephew is a global medical device company. The company markets clinically superior products, principally in orthopaedics, endoscopy and wound management to deliver cost-effective solutions, significant physicianadvantage and real patient benefits. A continuous process of supplying new and innovative...

See More

Key Turning Points

3rd Resistance Point 34.23
2nd Resistance Point 34.03
1st Resistance Point 33.76
Last Price 33.99
1st Support Level 33.28
2nd Support Level 33.08
3rd Support Level 32.81

See More

52-Week High 38.79
Last Price 33.99
Fibonacci 61.8% 33.02
Fibonacci 50% 31.24
Fibonacci 38.2% 29.46
52-Week Low 23.69

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar